USPTO Patent Applications - Pharma (A61K)

Nasal Cannabidiol Composition Patent, Frank-Markus Leweke, Apr 9

Nasal Cannabidiol Composition Patent, Frank-Markus Leweke, Apr 9

Active Premix Aluminum Zirconium Salts Antiperspirant

USPTO published patent application US20260096968A1 by Wade Charles Henke, Shawn David McConaughy, and David Frederick Swaile covering a particulate active premix composition containing an aluminum zirconium salt, an amino acid, and greater than 1% of an alkali metal salt for use in antiperspirant products.

UV Absorbing System With Physical Material Coloring Agent

USPTO published L'OREAL's patent application (US20260096967A1) for UV-absorbing compositions containing physical UV-attenuating materials and coloring agents. The application covers methods of making and using such cosmetic compositions for sun protection. The application was filed October 3, 2025.

L'OREAL UV Absorbing Composition with Physical Filters and Three Emollients

USPTO published L'OREAL's patent application (US20260096966A1) for a UV-absorbing composition combining at least one physical UV-attenuating material with an emollient system containing at least three emollients. The invention includes methods of making and using such compositions for topical applications. The application was filed on October 3, 2025, under Application No. 19349244.

L'OREAL UV Emulsion Patent with Physical UV-Absorbing System

USPTO published L'OREAL's patent application US20260096965A1 for emulsion compositions containing a UV-absorbing system with physical UV-attenuating material and spherical plus amorphous particulate materials. The patent covers methods of making and using such compositions for UV protection. The application was filed October 4, 2024.

UV-Absorbing Emulsion with Physical UV-Attenuating Material, Surfactant, and Thickener

USPTO published L'OREAL's patent application (US20260096964A1) for UV-absorbing emulsion compositions containing physical UV-attenuating material, surfactant, and thickening agents. The application was filed on October 4, 2024, under Application No. 18906424. Inventors include Anil Shah, David Enoch Gee II, Brian Bodnar, and Margaret Kindschuh. This patent publication affects cosmetics and personal care product manufacturers developing UV-protective formulations. Companies should review the claims to assess potential overlap with their own product development pipelines and IP strategies.

L'OREAL UV Absorbing System with Oil for Preventing Material Aggregation

The USPTO published L'OREAL's patent application (US20260096963A1) for a UV absorbing composition combining physical UV-attenuating materials with oils to inhibit particle aggregation. The invention targets improved stability in sunscreen and cosmetic formulations. The application was filed on October 4, 2024, under application number 18906290.

Active Premix for Antiperspirant Products Patent Application

The USPTO published patent application US20260096962A1 covering a particulate active premix composition for antiperspirant products. The composition combines basic aluminum chloride of formula Al2(OH)3.778Cl2.222 to Al2(OH)5.048Cl0.952, an amino acid, an alkaline earth metal salt, and greater than 1% of an alkali metal salt and/or magnesium chloride. Inventors: Wade Charles Henke, Shawn David McConaughy, and David Frederick Swain.

Particulate Active Premix Antiperspirant Aluminum Chloride Apr 09

Particulate Active Premix Antiperspirant Aluminum Chloride Apr 09

Liposome Composition Comprising Sphingomonas Olei Culture Extract for Skin Delivery

USPTO published patent application US20260096958A1 by six inventors including Won Woo Choi and Byong Jun Choi for a liposome composition encapsulating Sphingomonas olei culture extract for enhanced skin regeneration and transdermal absorption. The application covers cosmetic compositions for topical skin delivery applications, classified under CPC codes A61K 8/14 and A61Q 19/00.

Aerosol Antiperspirant Composition with Basic Aluminum Chloride Salt Formula

USPTO published patent application US20260096955A1 for an aerosol antiperspirant composition containing a basic aluminum chloride salt (formula Al2(OH)3.778Cl2.222 to Al2(OH)5.048Cl0.952), an amino acid, an alkaline earth metal salt, and greater than 1% of an alkali metal salt and/or magnesium chloride. The concentrate includes a particulate active premix, carrier, and fragrance. The application names five inventors and was filed October 3, 2025.

Doxycycline Mouthwash for COVID-19 Prevention

USPTO published patent application US20260091045A1 for a preventative mouthwash containing doxycycline (100-400mg dosage) for COVID-19 infection prevention. Inventor Bruce Roseman's application describes a gargling method using 5-20mL of the mouthwash twice daily for 5-10 days. The application was filed October 2, 2024 and published April 2, 2026.

Carbasalate Calcium Application for Hydrocephalus Treatment

The USPTO published patent application US20260091044A1 by Tianjin University covering the use of carbasalate calcium as the sole or primary active ingredient for treating hydrocephalus. The application includes zebrafish model experimental data demonstrating significant reduction in fourth ventricle area and improvements in swimming metrics. No regulatory compliance deadlines or penalties apply to this patent application publication.

Aqueous Pharmaceutical Formulation of Hydrocortisone Sodium Phosphate and Monothioglycerol

The USPTO published patent application US20260091042A1 filed by Antares Pharma, Inc. (inventors Xiaoming Chen, Shaowei Ong) covering aqueous pharmaceutical formulations comprising hydrocortisone sodium phosphate and monothioglycerol as an antioxidant, with optional buffer components including monobasic/dibasic sodium phosphate or disodium EDTA. The application also discloses methods of treating diseases or disorders by administering the formulation. This is routine intellectual property protection activity for a pharmaceutical formulation invention.

Compositions and Methods for Treating Mycobacterium Infections

USPTO published patent application US20260091043A1 for compositions and methods treating infections caused by Mycobacteriaceae family pathogens, including those causing tuberculosis. Inventors John David Wild, Jeremy Joseph Yang, and Sean Ekins filed the application on September 20, 2023. The application claims priority to Application No. 19113756 and covers novel therapeutic approaches to bacterial infections.

Methods of Treating Heavy Menstrual Bleeding

USPTO published patent application US20260091041A1 for methods of treating heavy menstrual bleeding with or without uterine fibroids. The application claims a method using compound 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid or salts thereof in combination with estrogens and progestogens. Fifteen inventors are named including Kristof Chwalisz, Jane Castelli-Haley, and others.

PFIC Treatment Methods Using IBAT Inhibitor Odevixibat

USPTO published patent application US20260091040A1 for methods of treating progressive familial intrahepatic cholestasis (PFIC) using IBAT inhibitor odevixibat. Inventors include Per-Göran Gillberg, Jan Mattsson, Pat Horn, and Paresh Soni. The application covers reducing pruritus scores, serum bile acid concentration, improving liver parameters, height normalization, weight improvement, and sleep quality.

Sepiapterin Methods for BH4 Disorders

USPTO published patent application US20260091037A1 for sepiapterin compositions and methods treating BH4-related disorders. Inventors Neil Smith and Jonathan Reis filed the application on May 13, 2025. The application covers methods for increasing sepiapterin plasma, CSF, and brain exposure for therapeutic use.

Elagolix dosing regimens for GnRH receptor antagonists

USPTO published patent application US20260091036A1 for dosing regimens of Elagolix (a GnRH receptor antagonist) and related compounds. The application claims methods to minimize bone mineral density changes in subjects suffering from endometriosis, adenomyosis, PCOS, or uterine fibroids. Filing date August 26, 2025.

Modified Release Minoxidil Compositions and Methods for Oral Administration

The USPTO published patent application US20260091035A1 by inventor Reid Waldman covering modified release minoxidil pharmaceutical formulations for oral daily dosing to treat hair loss. The application claims compositions including slow modified release vehicles containing minoxidil or pharmaceutically acceptable salts, optionally combined with additional active agents. Filing date was December 9, 2025.

Modified Release Minoxidil for Hair Loss Treatment

The USPTO published patent application US20260091034A1 by inventor Reid Waldman for a modified release oral formulation of minoxidil for treating hair loss. The application discloses pharmaceutical compositions including daily doses of modified release minoxidil, potentially combined with additional active agents, delivered via a slow release vehicle. The filing date is December 4, 2025, with publication on April 2, 2026.

FGFR3 Antagonist for Skeletal Disorders Treatment

The USPTO published patent application US20260091033A1 for an FGFR3 antagonist for treating skeletal disorders linked to abnormal FGFR3 activation. The application, filed by inventors LEGEAI-MALLET, MUNNICH, BUSCA, and BARBAULT on January 15, 2025, covers compositions and methods for treatment. This publication represents a new patent application and creates no immediate compliance obligations for industry.

Amorphous Solid Dispersions Patent - Intra-Cellular Therapies

USPTO published patent application US20260091032A1 by Intra-Cellular Therapies, Inc. for stable amorphous solid dispersions of a quinoxaline-derived compound with potential applications in neurological and metabolic disorders. The application, filed August 6, 2025, contains 29 CPC classifications spanning formulations, compounds, and therapeutic indications.

CGRP Receptor Antagonists for Treating Chemotherapy-Induced Nausea and Vomiting

The USPTO published patent application US20260091031A1 by inventor Alberto Chiarugi covering a method of using CGRP receptor antagonists (gepants) for treating chemotherapy-induced nausea and vomiting (CINV). The application claims the use of these migraine-approved drugs to target CGRP neuropeptides to prevent and counteract drug-induced nausea including CINV.

HIGH-DOSE NALOXONE FORMULATION

The USPTO published patent application US20260091030A1 for high-dose Naloxone formulations designed to treat ultra-potent synthetic opioid overdose. Invented by Gita Shankar and Suresh Potharaju, the formulation comprises naloxone hydrochloride with preservatives, buffering agents, and tonicity modifiers. The application was filed September 1, 2023, and published April 2, 2026.

Pridopidine for ALS Treatment

USPTO published patent application US20260091028A1 by Prilenia Neurotherapeutics Ltd. for a method of treating amyotrophic lateral sclerosis (ALS) using pridopidine. The application claims therapeutic use of pridopidine or a pharmaceutically acceptable salt for human subjects afflicted with ALS. Application No. 19391284 was filed on 2025-11-17.

Stilbene Derivatives as AHR Regulators with Improved Photostability

The USPTO published patent application US20260091027A1 for stilbene derivatives serving as aryl hydrocarbon receptor (AHR) regulators with improved photostability over the marketed drug Benvitimod. The application, filed September 19, 2023 under Application No. 19113670, covers compounds of formula I-1, their stereoisomers, salts, and prodrugs, along with preparation methods for gram-to-kilogram scale synthesis.

Methods of Treating Inflammatory Diseases with Formula I and II Compounds

The USPTO published patent application US20260091026A1 covering compounds of Formula (I) and Formula (II), and their use in treating inflammatory diseases. The application was filed December 5, 2025, and published April 2, 2026, naming inventors Robert Joseph Moreau, Naomi S. Rajapaksa, David C. Tully, and others. The claimed subject matter includes novel compounds, pharmaceutical compositions, and methods of treatment for inflammatory diseases and disorders.

Pharmaceutical Composition for Treating Fatty Liver Disease

USPTO published Shionogi & Co., Ltd.'s patent application US20260091022A1 for a pharmaceutical composition treating fatty liver disease. The application was filed December 9, 2025, and published April 2, 2026, covering a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof. CPC classifications are A61K 31/4184 and A61P 1/16.

Seaweed Polyphenol Antioxidant Extract System and Method

The USPTO published patent application US20260091326A1 by inventor Sabrena Mackenzie, disclosing a process for producing a high-quality polyphenol-containing antioxidant extract from seaweed biomass. The process yields residual biomass available for alginate and fucoidan production. The application (No. 19110368) was filed September 8, 2023 and classified under CPC codes B01D 11/0288 and A61K 36/03.

Gel-Chewable Dosage Form Patent Application

USPTO published patent application US20260091023A1 for a gel-chewable dosage form drug delivery system. Inventors Vipul Dave and Anurag Pandey disclose a formulation with multiple active pharmaceutical ingredients, where at least one is encapsulated in lipid material embedded in the gel base. The invention includes methods for treating diseases or disorders of the gastrointestinal tract.

PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE

USPTO published patent application US20260091024A1 for substituted riluzole prodrug compositions useful for treating cancers including melanoma, breast cancer, brain cancer, and prostate cancer. The prodrugs are designed for oral administration with enhanced stability to hepatic metabolism, releasing riluzole in plasma via enzymatic or biophysical processes. Inventors include Jay Edward Wrobel, Allen B. Reitz, Jeffrey Claude Pelletier, Garry Robert Smith, and Haiyan Bian. Application No. 19064963 was filed February 27, 2025.

Neurotoxin Compositions for Treating Gastroparesis

USPTO published patent application US20260091094A1 disclosing neurotoxin compositions and methods for treating gastroparesis. Inventors Gregory F. Brooks and Eric Carter filed the application on December 9, 2025, under application number 19413766. The publication constitutes prior art as of April 2, 2026.

Methods and Systems for Ablation of the Renal Pelvis

Verve Medical, Inc. filed a patent application (US20260091000A1) with the USPTO on April 2, 2026 for methods and systems of renal pelvis ablation to treat renal nerves. The application covers apparatus and systems for delivering heat or extracting heat through the renal pelvis wall, or delivering active substances to ablate tissue lining. Inventors include Terrence J. Buelna, Adam Gold, and Rahul Rao.

Pharmaceutical Compositions Comprising Maralixibat and Uses Thereof

The USPTO published patent application US20260090993A1 by Mirum Pharmaceuticals, Inc. for pharmaceutical compositions comprising maralixibat as an active ingredient. The application covers the use of these compositions as solid dosage drug products for treating cholestatic pruritus and cholestatic liver disease. The application was filed on April 9, 2025, and contains 8 CPC classifications related to drug formulations.

Tablet Formulation Patent for HIV Capsid Inhibitor and NRTTI

The USPTO published patent application US20260090994A1 for tablet formulations combining an HIV capsid inhibitor with a nucleoside reverse transcriptase translocation inhibitor (NRTTI) for treating HIV infections. The application was filed on August 29, 2025 under Application No. 19314157. Inventors include Benjamin Chal, Jay Poorna Reddy, Dhananjay Devidas Marathe, and eight others.

Pouch Dispensing System for Topical Anesthetic

USPTO published patent application US20260090987A1 for a pouch dispensing system for topical anesthetic. Invented by Andrew Albee, the application (No. 19347190, filed 2025-10-01) covers an apparatus including a pouch, cover material, and topical anesthetic for oral application.

Fat tissue drug delivery system for cancer treatment

USPTO published patent application US20260090990A1 for a fat tissue-based drug delivery system designed for cancer treatment. The invention comprises fat tissue or derivatives thereof for delivering molecules, preferably antitumor drugs. The application (No. 19307845) was filed August 22, 2025, with inventors including Augusto Pessina, Giulio Alessandri, Carlo Tremolada, and Offer Zeira.

Hydroxypropyl methylcellulose powder compositions and applications

USPTO published patent application US20260090992A1 for homogenized hydroxypropyl methylcellulose powder compositions containing chemical signaling agents and optionally biologically active agents, with particle diameters of 20-500μm. Inventors: Todor A. Popov and Peter David Josling. Application No. 19409272 was filed December 4, 2025.

Mascara Composition with Sunflower Seed Wax

L'ORÉAL published patent application US20260090978A1 for mascara composition containing sunflower seed wax, tribehenin, and behenyl behenate. The invention provides improved aesthetics with total wax content of 5-35% by weight and combined wax blend of 5-20%. Application filed September 2024 with inventors David CHAN and Geoffrey WHITE.

Contact Lenses with Medicament Coating for Drug Release in Glaucoma Treatment

MEDIPRINT OPHTHALMICS INC. filed patent application US20260090984A1 for contact lenses incorporating medicament coatings for controlled drug release, specifically targeting glaucoma treatment through sustained delivery of drugs such as bimatoprost. The application covers the lens composition including N-vinylpyrrolidone, soaking solutions, and methods for loading and refreshing drug-eluting contact lenses. This patent application (No. 19411056, filed December 5, 2025) names six inventors including Praful Doshi and Brandon Huang.

Pediatric parenteral nutrition, oil-in-water emulsion, multi-chamber containers

USPTO published patent application US20260090983A1 for pediatric parenteral nutrition formulations comprising lipid emulsions in oil-in-water form. The application also covers multi-chamber containers for separating carbohydrate, amino acid, and lipid formulations until administration. Inventors include Jean-Luc Trouilly, Mary Hise Brown, Laurent Jeannin, Julien Hecq, and Julie Fahier.

Transdermal Delivery Formulations

USPTO published patent application US20260090981A1 for LifeActive, Inc., covering transdermal delivery formulations combining weak organic acids with fatty acid microemulsions for epicutaneous administration of therapeutic agents, drugs, and nutrients. The formulations are designed for use in high humidity conditions such as showers or saunas.

Cosmetic Compositions for Skin Firming Using Escin Extracts

USPTO published Mary Kay Inc.'s patent application for cosmetic compositions containing escin and botanical extracts for treating sagging, loose skin and improving facial contouring. The application includes methods comprising topical application of compositions with escin, Ascophyllum nodosum extract, caffeine, Coleus barbatus extract, and other plant-based ingredients. This is an informational publication with no regulatory compliance requirements.

Cosmetic Uses of Phaeodactylum Tricornutum Hydrolysate

USPTO published patent application US20260090979A1 by MICROPHYT covering cosmetic uses of a hydrolysate derived from an ethanolic extraction coproduct of the microalgae Phaeodactylum tricornutum. The invention targets skin exfoliation and reduction of skin microrelief for cosmetic and nutraceutical applications.

Water-in-oil cosmetic composition

USPTO published patent application US20260090977A1 for a water-in-oil cosmetic composition comprising specific silicone components (A) and (B) along with silicone powder (C), designed to improve stability, spreadability, and layered makeup durability. The application was filed September 7, 2023, with inventors Masaru Miyauchi, Masayuki Konishi, Yoshinori Inokuchi, and Ryuji Horiguchi.

Cosmetic Base Patent with Polymer Formula for Moisturizing Effect

Shiseido Company, Ltd. filed USPTO Patent Application US20260090976A1 for a cosmetic base composition containing a polymer formula designed to provide both use sensation and moisturizing effect. The polymer has a number-average molecular weight not exceeding 10,000 and an IOB value between 0.4 and 1.8. The application was published on April 2, 2026 with Filing Date August 31, 2023.

Sodium DNA Lipid Nanoparticle Drug Delivery Patent

USPTO published patent application US20260090968A1 for a lipid nanoparticle composition containing sodium DNA as an active ingredient, with applications in pharmaceutical drug delivery systems. The composition includes sodium dilauramidoglutamide lysine as an amphiphilic surfactant, distearoylphosphatidylcholine as an auxiliary surfactant, cholesterol as a stabilizer, and auxiliary stabilizers including PEG-120 stearate, polyglyceryl-4 caprate, and PEG-PCL copolymer. Filing date is October 10, 2023.

Cellular Oxidative and Mitochondrial Stress Protection Compositions

NUCHIDO LIMITED filed USPTO Patent Application US20260090969A1 for compositions protecting cells from oxidative and mitochondrial stress. The application discloses a combination of bioactive compounds including NMN, NR, resveratrol, curcumin, and other cellular stress protectors for pharmaceutical and cosmetic applications. Published April 2, 2026.

Composition for Promoting the Skin Microbiome

USPTO published patent application US20260090967A1 for a skin microbiome promoting composition. The application claims a combination of carbon sources (glucose, fructose, saccharose, maltose, maltodextrin, pyruvic acid, pyruvate, lactic acid and lactate) and nitrogen sources (alanine, glycine, arginine and urea), and/or caprylic/capric triglycerides. Inventors include Jennifer Huepeden, Mirja Laschet, Karen Tom Dieck, Heike Foelster, and Sabine Sellckau.